- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Key Metrics
- Market Cap (In Cr) 47588.78
- Beta 0.42
- Div. Yield (%) 0.53
- P/B 2.83
- TTM P/E 18.31
- Peg Ratio 6.59
- Sector P/E 30.05
- D/E -
- Open Price 470
- Prev Close 470.15
Analysis
-
1 Week9.86%
-
3 Months4.23%
-
6 Month30.34%
-
YTD11.95%
-
1 Year14.88%
- 26% Low risk
- 26% Moderate risk
- 26% Balanced Risk
- 26% High risk
- 26% Extreme risk
31 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
- Ratings
- Current
- Strong Sell
- 2
- Sell
- 2
- Hold
- 9
- Buy
- 9
- Strong Buy
- 9
Zydus Lifesciences News
Zydus Lifesciences gets USFDA nod for thyroid hormone deficiency drug
1 min read . 28 Nov 2022Zydus Lifesciences' share buyback opens today. What investors should know
1 min read . 23 Jun 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 15265.2
- Selling/ General/ Admin Expenses Total
- 5385.9
- Depreciation/ Amortization
- 713
- Other Operating Expenses Total
- 288.4
- Total Operating Expense
- 12523.1
- Operating Income
- 2742.1
- Net Income Before Taxes
- 2838.1
- Net Income
- 4487.3
- Diluted Normalized EPS
- 21.01
- Period
- 2022
- Total Assets
- 27795.4
- Total Liabilities
- 10795.8
- Total Equity
- 16999.6
- Tangible Book Valueper Share Common Eq
- 102.64
- Period
- 2022
- Cashfrom Operating Activities
- 2078.2
- Cashfrom Investing Activities
- 1154.4
- Cashfrom Financing Activities
- -868.3
- Net Changein Cash
- 2372.9
- Period
- 2021
- Total Revenue
- 14403.5
- Selling/ General/ Admin Expenses Total
- 5254.6
- Depreciation/ Amortization
- 669.6
- Other Operating Expenses Total
- 301
- Total Operating Expense
- 11873
- Operating Income
- 2530.5
- Net Income Before Taxes
- 2399.2
- Net Income
- 2133.6
- Diluted Normalized EPS
- 23.38
- Period
- 2021
- Total Assets
- 23884.7
- Total Liabilities
- 10892.4
- Total Equity
- 12992.3
- Tangible Book Valueper Share Common Eq
- 62.61
- Period
- 2021
- Cashfrom Operating Activities
- 3185.1
- Cashfrom Investing Activities
- -722.5
- Cashfrom Financing Activities
- -2548.9
- Net Changein Cash
- -90.5
- Period
- 2020
- Total Revenue
- 14253.1
- Selling/ General/ Admin Expenses Total
- 5142.8
- Depreciation/ Amortization
- 696.5
- Other Operating Expenses Total
- 804.3
- Total Operating Expense
- 12515.1
- Operating Income
- 1738
- Net Income Before Taxes
- 1495.4
- Net Income
- 1176.6
- Diluted Normalized EPS
- 14.4
- Period
- 2020
- Total Assets
- 23686.6
- Total Liabilities
- 13310.9
- Total Equity
- 10375.7
- Tangible Book Valueper Share Common Eq
- 35.14
- Period
- 2020
- Cashfrom Operating Activities
- 2505.4
- Cashfrom Investing Activities
- -1012.3
- Cashfrom Financing Activities
- -1094.2
- Net Changein Cash
- 398.9
- Period
- 2019
- Total Revenue
- 13165.6
- Selling/ General/ Admin Expenses Total
- 4287.6
- Depreciation/ Amortization
- 598.6
- Other Operating Expenses Total
- 592.2
- Total Operating Expense
- 10783.4
- Operating Income
- 2382.2
- Net Income Before Taxes
- 2382.1
- Net Income
- 1848.8
- Diluted Normalized EPS
- 18.12
- Period
- 2019
- Total Assets
- 23483.1
- Total Liabilities
- 13096.8
- Total Equity
- 10386.3
- Tangible Book Valueper Share Common Eq
- 32.51
- Period
- 2019
- Cashfrom Operating Activities
- 1543.2
- Cashfrom Investing Activities
- -4238.7
- Cashfrom Financing Activities
- 1884.6
- Net Changein Cash
- -810.9
- Period
- 2018
- Total Revenue
- 11954.4
- Selling/ General/ Admin Expenses Total
- 3850
- Depreciation/ Amortization
- 538.8
- Other Operating Expenses Total
- 467
- Total Operating Expense
- 9643.4
- Operating Income
- 2311
- Net Income Before Taxes
- 2330.8
- Net Income
- 1775.8
- Diluted Normalized EPS
- 17.65
- Period
- 2018
- Total Assets
- 18065.3
- Total Liabilities
- 9320.8
- Total Equity
- 8744.5
- Tangible Book Valueper Share Common Eq
- 59.37
- Period
- 2018
- Cashfrom Operating Activities
- 919.3
- Cashfrom Investing Activities
- -973.7
- Cashfrom Financing Activities
- 51.5
- Net Changein Cash
- -2.9
- Period
- 2017
- Total Revenue
- 9572.3
- Selling/ General/ Admin Expenses Total
- 3150.6
- Depreciation/ Amortization
- 373.3
- Other Operating Expenses Total
- 400.7
- Total Operating Expense
- 8040.7
- Operating Income
- 1531.6
- Net Income Before Taxes
- 1614.6
- Net Income
- 1487.7
- Diluted Normalized EPS
- 14.57
- Period
- 2017
- Total Assets
- 15220.7
- Total Liabilities
- 8260.7
- Total Equity
- 6960
- Tangible Book Valueper Share Common Eq
- 43.91
- Period
- 2017
- Cashfrom Operating Activities
- 1311.7
- Cashfrom Investing Activities
- -2871.9
- Cashfrom Financing Activities
- 2315.8
- Net Changein Cash
- 755.6
- Period
- 2022-12-31
- Total Revenue
- 4362.3
- Selling/ General/ Admin Expenses Total
- 689
- Depreciation/ Amortization
- 181.6
- Other Operating Expenses Total
- 1206.9
- Total Operating Expense
- 3587.9
- Operating Income
- 774.4
- Net Income Before Taxes
- 780.1
- Net Income
- 622.9
- Diluted Normalized EPS
- 6.15
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 4134.7
- Selling/ General/ Admin Expenses Total
- 671.7
- Depreciation/ Amortization
- 181.8
- Other Operating Expenses Total
- 1053.3
- Total Operating Expense
- 3501.2
- Operating Income
- 633.5
- Net Income Before Taxes
- 642.8
- Net Income
- 522.5
- Diluted Normalized EPS
- 5.1
- Period
- 2022-09-30
- Total Assets
- 25629.3
- Total Liabilities
- 8964.3
- Total Equity
- 16665
- Tangible Book Valueper Share Common Eq
- 100.38
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 1129.1
- Cashfrom Investing Activities
- -539.6
- Cashfrom Financing Activities
- -3063.8
- Net Changein Cash
- -2475.6
- Period
- 2022-06-30
- Total Revenue
- 4072.7
- Selling/ General/ Admin Expenses Total
- 681
- Depreciation/ Amortization
- 180.7
- Other Operating Expenses Total
- 1049.4
- Total Operating Expense
- 3423.3
- Operating Income
- 649.4
- Net Income Before Taxes
- 681
- Net Income
- 518.3
- Diluted Normalized EPS
- 5.16
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 3800
- Selling/ General/ Admin Expenses Total
- 546.7
- Depreciation/ Amortization
- 162.3
- Other Operating Expenses Total
- 1018.1
- Total Operating Expense
- 2959.5
- Operating Income
- 840.5
- Net Income Before Taxes
- 881
- Net Income
- 397.4
- Diluted Normalized EPS
- 4.88
- Period
- 2022-03-31
- Total Assets
- 27795.4
- Total Liabilities
- 10795.8
- Total Equity
- 16999.6
- Tangible Book Valueper Share Common Eq
- 102.64
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 2078.2
- Cashfrom Investing Activities
- 1154.4
- Cashfrom Financing Activities
- -868.3
- Net Changein Cash
- 2372.9
- Period
- 2021-12-31
- Total Revenue
- 3655
- Selling/ General/ Admin Expenses Total
- 585.5
- Depreciation/ Amortization
- 183.2
- Other Operating Expenses Total
- 969.7
- Total Operating Expense
- 3085.7
- Operating Income
- 569.3
- Net Income Before Taxes
- 599
- Net Income
- 500.4
- Diluted Normalized EPS
- 4.89
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Forecast
Forecast
Technical
- 5 Day432.17
- 10 Day433.57
- 20 Day438.19
- 50 Day423.42
- 100 Day414.32
- 300 Day386.79
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Torrent Pharmaceuticals
- 1536.55
- -3.25
- -0.21
- 1722.7
- 1235.88
- 51846.46
- Abbott India
- 20755.65
- -125.7
- -0.6
- 22481.8
- 15426.74
- 44352.08
- Zydus Lifesciences
- 474.15
- 4
- 0.85
- 476.35
- 319.4
- 43995.45
- Alkem Laboratories
- 3052
- -17.25
- -0.56
- 3720
- 2835
- 36482.27
- Lupin
- 741.5
- -3.55
- -0.48
- 870
- 583.05
- 33633.49
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Torrent Pharmaceuticals
- 47.8
- 8.71
- 16.36
- 10.81
- Abbott India
- 55.53
- 15.73
- 27.07
- 14.45
- Zydus Lifesciences
- 20.69
- 2.62
- 17
- 13.51
- Alkem Laboratories
- 22.18
- 4.22
- 18.92
- 14.07
- Lupin
- 140.44
- 2.77
- 0.08
- 0.13
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 25.02%
- 253,263,953
- Llife Insurance Corporation of India
- 6.23%
- 63,090,404
- Others
- 1.63%
- 16,526,762
- Others
- 6.23%
- 63,069,202
- Kotak Flexicap Fund
- 2.44%
- 24,673,918
- Others
- 3.11%
- 31,585,398
- Others
- 2.51%
- 25,439,386
- Others
- 0.82%
- 8,346,403
- Others
- 0.81%
- 8,239,815
- Others
- 0.39%
- 3,958,853
- HUF
- 0.21%
- 2,107,319
- Clearing Members
- 0.05%
- 499,362
- Trusts
- 0.05%
- 495,717
- LLP
- 0.03%
- 278,762
- Unclaimed or Suspense or Escrow Account
- 0.02%
- 242,675
- Others
- 0.15%
- 1,537,294
- Others
- 0.15%
- 1,478,733
- Others
- 0.07%
- 756,684
- Others
- 0.04%
- 378,412
- Others
- 0.03%
- 329,463
- Others
- 0.01%
- 101,475
- Others
- 0.01%
- 65,546
- Others
- 0%
- 47,394
- Others
- 0%
- 13,091
- Others
- 0%
- 1,284
- Others
- 0%
- 300
- Others
- 0%
- 300
- Others
- 0%
- 1
- Promoter & Promoter Group Shareholding
- 74.98%
- 758,940,186
- Zydus Family Trust(Mr. Pankaj R. Patel,Mrs. Pritiben P. Patel and Dr. Sharvil P. Patel-Trustees)
- 74.96%
- 758,788,706
- Pripan Investment Private Limited
- 0%
- 17,821
- Taraben Patel Family Will Trust(Mr.Pankaj Ramanbhai Patel and Dr. Sharvil Pankajbhai Patel-Trustees)
- 0%
- 14,851
- Pankaj Ramanbhai Patel
- 0%
- 44,553
- Pankaj Ramanbhai Patel HUF (Pankaj Ramanbhai Patel-Karta)
- 0%
- 29,702
- Shivani Pankajbhai Patel
- 0%
- 14,851
- Pritiben Pankajbhai Patel
- 0%
- 14,851
- Sharvil Pankajbhai Patel
- 0%
- 14,851
Shareholding Pattern
Shareholding Trend
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 03-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- 20-May-22
- Audited Results, Dividend & Buy Back
- 03-Feb-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- 11-Aug-21
- Quarterly Results
- 27-May-21
- Audited Results & Final Dividend
- 05-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 10-Aug-22
- 21-May-22
- AGM
- 18-Feb-22
- 25-Jan-22
- EGM
- 11-Aug-21
- 27-May-21
- AGM
- 11-Jun-21
- 18-May-21
- EGM
- -
- 20-May-22
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 20-May-22
- 29-Jul-22
- 28-Jul-22
- 2.5
- 27-May-21
- -
- 28-Jul-21
- 3.5
Company Profile
ABOUT Zydus Lifesciences
- Industry Biotechnology & Drugs
- ISIN INE010B01027
- BSE Code 532321
- NSE Code ZYDUSLIFE
Zydus Lifesciences Ltd., formerly Cadila Healthcare Limited, is an India-based life sciences company. The Company is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The Company has a pipeline for Biologics and Vaccines. The Company offers Lipaglyn to treat diabetic dyslipidemia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The Company in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The Company provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The Company has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.
MANAGEMENT
- Nitin Parekh Chief Financial Officer
- Dhaval Soni Company Secretary, Chief Compliance Officer
- Sharvil Patel Managing Director, Executive Director
- Ganesh Nayak Executive Director
Company Summary
ZYDUS LIFESCIENCES SUMMARY
Zydus Lifesciences is trading 0.85% upper at Rs 474.15 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 478.95 & 468.75. Zydus Lifesciences has given 11.95% in this year & 9.86% in the last 5 days.
Zydus Lifesciences has TTM P/E ratio 18.31 as compared to the sector P/E of 30.05. There are 31 analysts who have initiated coverage on Zydus Lifesciences. There are 9 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.
The company posted a net profit of 622.9 Crores in its last quarter.
Listed peers of Zydus Lifesciences include Torrent Pharmaceuticals (-0.21%), Abbott India (-0.6%), Zydus Lifesciences (0.85%) etc.
Zydus Lifesciences has a 74.98% promoter holding & 25.02% public holding.
FAQs about Zydus Lifesciences
- 2 analysts have given a strong sell rating
- 2 analysts have given a sell rating
- 9 analysts have given a hold rating
- 9 analysts have given a buy rating
- 9 analysts have given a strong buy rating
- TTM P/E: 18.31
- Sector P/E: 30.05
- Dividend Yield: 0.53%
- D/E ratio: -